We are international
Donate
TEXT SIZE   


Dr. Siegel - Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
David Siegel, MD
Hackensack University Medical Center
Hackensack, New Jersey
USA
12.02.10


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles